Log in to your Inderes Free account to see all free content on this page.

Sedana Medical

20.05

SEK

+5.75 %

SEDANA

NASDAQ Stockholm

Medical Equipment & Services

Health Care

1 following

+5.75%

+67.64%

-14.68%

-17.15%

-13.43%

-13.35%

-77.34%

-39.97%

+236.97%

Sedana Medical is a medical technology company. The company currently works with AnaConDa technology, which includes the transformation of liquid into gas. The technique is usually used for intensive care patients during anesthesia and differs from the traditional treatment previously given intravenously with drugs. The company is headquartered in Danderyd.

Market cap

1.99B SEK

Turnover

14.8M SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

13.2.

2025

Annual report '24

6.5.

2025

Interim report Q1'25

15.5.

2025

General meeting '24

ShowingAll content types

Regulatory press release12/19/2024, 6:59 PM

Sedana Medical announces positive high-level results of its first pivotal trial in the United States (INSPiRE-ICU 1)

Regulatory press release12/13/2024, 4:35 PM

Sedana Medical receives a positive decision to include children (3-17 years) into the Sedaconda® (isoflurane) indication

Regulatory press release11/29/2024, 2:00 PM

Sedana Medical completes the acquisition of its main supplier

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release11/5/2024, 7:00 AM

Change in Sedana Medical’s Nomination Committee for the 2025 Annual General Meeting

Press release10/28/2024, 5:38 PM

Redeye: Sedana Medical Q3 - A blow but no curtains-down event

Regulatory press release10/24/2024, 5:00 AM

Sedana Medical AB’s Interim report January-September 2024

Regulatory press release10/18/2024, 6:00 AM

Sedana Medical’s Nomination committee for the 2025 Annual General Meeting

Press release10/7/2024, 6:00 AM

Invitation to presentation of Sedana Medical’s interim report for the third quarter 2024

Press release8/2/2024, 8:21 AM

Redeye: Sedana Medical Q2 - The US story comes closer

Regulatory press release7/23/2024, 5:00 AM

Sedana Medical AB's Interim report January-June 2024

Regulatory press release7/22/2024, 6:00 PM

Sedana Medical to acquire its main supplier to take control of supply chain and reduce cost of goods

Press release7/16/2024, 6:00 AM

Invitation to presentation of Sedana Medical's interim report for the second quarter 2024

Press release5/29/2024, 6:00 AM

Sedana Medical completes patient recruitment for its clinical program in the US

Regulatory press release5/22/2024, 2:30 PM

Report from Sedana Medical's annual general meeting on 22 May 2024

Press release4/26/2024, 2:22 PM

Redeye: Sedana Medical Q1 - Set to beat conservative sales target

Regulatory press release4/25/2024, 5:00 AM

Sedana Medical AB's Interim report January-March 2024

Press release4/25/2024, 4:45 AM

Sedana Medical completes patient recruitment for INSPiRE-ICU 1 clinical trial in the US

Regulatory press release4/22/2024, 6:30 AM

Notice of Annual General Meeting in Sedana Medical

Regulatory press release4/15/2024, 7:02 PM

Sedana Medical publishes its Annual Report for 2023

Press release4/5/2024, 6:00 AM

Invitation to presentation of Sedana Medical's interim report for the first quarter 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.